Shares shifted sharply higher as investors bet on a strong first-quarter report from Mastek Limited, the mid-cap Indian IT services firm, ahead of its July 21 board meeting to approve Q1 FY27 results. The company will announce unaudited results on July 21, with an earnings call scheduled for July 22 at 12:30 PM IST. At ₹1,749.80, the stock is up 8.5% in a week — but the rally raises a question: is this momentum backed by fundamentals or just pre-earnings speculation?
A ₹2,849-Crore Order Book Gives Investors Something Real to Buy
The 12-month order backlog stood at ₹2,849.2 crore ($300.4 million) as of March 31, 2026, up 24.4% year-on-year. That pipeline — the work already contracted but not yet billed — gives Mastek better revenue visibility going into FY27 than it had a year ago. Management expects FY27 to deliver better performance, supported by strong order book momentum across healthcare, financial services, and retail.
UK Government Deals Are the Engine, But Concentration Is a Risk Mastek's UK business is its growth anchor. In March 2026, its UK subsidiary secured an engineering contract with the Home Office worth roughly £85 million ($110 million+) , on top of a five-year £49 million Home Office biometrics contract announced in February and a £15 million deal with the Financial Conduct Authority.
The UK and Europe business grew 21.8% in rupee terms during FY26, driven by a 95% healthcare sector surge. But heavy reliance on UK public-sector budgets means any shift in government spending could hit hard.
Margins Held Steady — Barely — Despite Rising Costs
Operating EBITDA margin (a measure of operating profit as a percentage of revenue) came in at 16.1% in Q4 FY26, down from 16.8% the prior quarter.
Management guides for 16–16.1% margins in FY27 , a modest target that suggests wage inflation and pricing pressure leave little room for upside. Full-year net profit was ₹404 crore, up 7.5% year-on-year — solid but not explosive.
The Valuation Gap: Analysts See Upside, but the Stock Has Suffered
Five analysts peg the average 12-month target at ₹2,002, with a high of ₹2,250 and a low of ₹1,600 — implying roughly 14% upside from today's price. The stock is trading at just 35.9% of its 52-week range (₹1,887–₹3,375) , meaning investors have already punished Mastek heavily. The Q1 print on July 21 will either confirm that the worst is behind the company — or show that margin headwinds are still tightening.